 NEWARK, Calif., June 15, 2021 PRNewswire -- Protagonist Therapeutics, Inc. Nasdaq: PTGX, a clinical stage biopharmaceutical company, today announced the pricing of its previously announced underwritten public offering of 3,046,358 shares of its common stock at a price to the public of 37.75 per share. 